| 46.46 Delayed Data As of Sep 20 |  +1.54 / +3.43%Today’s Change | 40.00 Today|||52-Week Range 46.60 | +7.03% Year-to-Date |
| Trovagene's Onvansertib Shows Response in Phase Ib AML Study Sep 20 / Zacks.com - Paid Partner Content | Aimmune's Peanut Allergy Drug Gets FDA Committee's Support Sep 16 / Zacks.com - Paid Partner Content |
| CGM Devices Gain Steam, Set New Trend in Diabetes Management Sep 20 / Zacks.com - Paid Partner Content | Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use Sep 13 / Zacks.com - Paid Partner Content |
| Alnylam Focuses on Pipeline Development Amid Competition Sep 19 / Zacks.com - Paid Partner Content | J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients Sep 12 / Zacks.com - Paid Partner Content |
| Alnylam Begins Phase III Study on Onpattro for New Indication Sep 17 / Zacks.com - Paid Partner Content | Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally Sep 11 / Zacks.com - Paid Partner Content |
| Abbott Partners With Sanofi to Upgrade Diabetes Management Sep 17 / Zacks.com - Paid Partner Content | Should Value Investors Buy Sanofi (SNY) Stock? Sep 09 / Zacks.com - Paid Partner Content |
| Previous close | 44.92 |
| Today’s open | 45.53 |
| Day’s range | 45.43 - 46.60 |
| Volume | 3,554,565 |
| Average volume (3 months) | 1,473,693 |
| Market cap | $109.1B |
| Earnings growth (last year) | +19.94% |
| Earnings growth (this year) | +4.16% |
| Earnings growth (next 5 years) | +4.00% |
| Revenue growth (last year) | +2.83% |
| P/E ratio | 29.5 |
| Price/Sales | 2.68 |
| Price/Book | 1.62 |
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | +1.81 | +1.58% |
| AZNAstraZeneca | +0.57 | +1.28% |
| ABBVAbbVie | +0.72 | +1.00% |
| GSKGlaxoSmithKline | +0.31 | +0.75% |
| Next reporting date | October 31, 2019 |
| EPS forecast (this quarter) | $0.99 |
| Annual revenue (last year) | $40.7B |
| Annual profit (last year) | $5.1B |
| Net profit margin | 12.53% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer Paul Hudson |
Chief Financial Officer & Executive Vice President Jean-Baptiste Chasseloup de Chatillon |
Corporate headquarters Paris, Ile-de-france |
